Evidence map›Paper›PMID 34928955›Full record

ArticlePLoS neglected tropical diseases2021

The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): A case study of bubonic plague.

Tsinjo Fehizoro Rasoanaivo, Josephine Bourner, Ravaka Niaina Randriamparany, Théodora Mayouya Gamana, Voahangy Andrianaivoarimanana, Mily Harijaona Raherivelo, Harivelo Randriamampionona, Minoarisoa Rajerison, Mihaja Raberahona, Alex Paddy Salam and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Tsinjo Fehizoro RasoanaivoInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Josephine BournerCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4687-8380
Ravaka Niaina RandriamparanyInstitut Pasteur de Madagascar, Antananarivo, Madagascar.ORCID 0000-0003-1942-0884
Théodora Mayouya GamanaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.ORCID 0000-0002-3508-2486
Voahangy AndrianaivoarimananaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Mily Harijaona RaheriveloService de Santé de District Ambositra, Ambositra, Madagascar.
Harivelo RandriamampiononaService de Santé de District Manandriana, Manandriana, Madagascar.
Minoarisoa RajerisonInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Mihaja RaberahonaCentre Infectiologie Charles Mérieux, Université d'Antananarivo, Antananarivo, Madagascar.ORCID 0000-0001-8857-5834
Alex Paddy SalamCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Tansy EdwardsLondon School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-6110-014X
Piero L OlliaroCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-1426-3680
Rindra Vatosoa RandremananaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Institut Pasteur de Madagascar · MGUniversity of Oxford · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Antananarivo · MG

Funding

Medical Research Council MR/R010161/1Wellcome TrustWellcome Trust 215091/Z/18/ZWellcome Trust 216273/Z/19/Z
6 · The paper itself

Abstract

backgroundAmong the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics for Neglected Tropical Diseases (NTDs) and diseases affecting the most vulnerable populations. Here we explore the impact of the pandemic on a clinical trial for plague therapeutics and strategies that have been considered to ensure research efforts continue.

methodsTo understand the impact of the COVID-19 pandemic on the trial accrual rate, we documented changes in patterns of all-cause consultations that took place before and during the pandemic at health centres in two districts of the Amoron'I Mania region of Madagascar where the trial is underway. We also considered trends in plague reporting and other external factors that may have contributed to slow recruitment.

resultsDuring the pandemic, we found a 27% decrease in consultations at the referral hospital, compared to an 11% increase at peripheral health centres, as well as an overall drop during the months of lockdown. We also found a nation-wide trend towards reduced number of reported plague cases. DISCUSSION: COVID-19 outbreaks are unlikely to dissipate in the near future. Declining NTD case numbers recorded during the pandemic period should not be viewed in isolation or taken as a marker of things to come. It is vitally important that researchers are prepared for a rebound in cases and, most importantly, that research continues to avoid NTDs becoming even more neglected.

Indexed as

COVID-19Health Impact AssessmentRandomized Controlled Trials as TopicResearchDisease NotificationEpidemiological MonitoringHumansMadagascarNeglected DiseasesPandemicsPatient Acceptance of Health CarePatient SelectionPlagueReferral and ConsultationTropical Medicine

Identifiers

PMID34928955
PMCPMC8722723
OpenAlexW4200322898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.